Pharmaceutical net sales totaled $4.5 billion and sales of nutritionals totaled $728 million in the second quarter of 2008, representing increases of 16% and 17%, respectively, compared to the prior year quarter.
The company has reported diluted EPS of $0.36 in the second quarter of 2008, an increase of 20% compared with $0.30 in the corresponding period of 2007.
The company has reported net earnings from continuing operations of $722 million in the second quarter of 2008, an increase of 23%, compared with $588 million posted for the same period in 2007.
James Cornelius, chairman and CEO of Bristol-Myers Squibb, said: “In addition to strong sales growth, we are making acquisitions, entering licensing agreements and investing in our pipeline, as we deliver on our commitments to patients and investors. We are also taking steps now to manage through future exclusivity losses. Our improvement initiatives are enabling us to better manage our costs and work more efficiently.”